Back to results
US 2013/0252967 A1Published application
8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
AssigneeAfraxis, Inc.
InventorsDavid Campbell, Sergio G. Duron, Benedikt Vollrath, Warren Wade
Life of this patent
Estimating the term…
Abstract
Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders.
Claims54
A compound having the structure of Formula I or a pharmaceutically acceptable salt or N-oxide thereof:
- wherein:
- R1 and R2 are each independently H or substituted or unsubstituted alkyl;
- or R1 and R2 together with the carbon to which they are attached form a C3-C6 cycloalkyl ring;
- p is 1, 2 or 3;
- ring A is aryl or heteroaryl;
- R3 is S(═O)R9 or —S(═O)2R9;
- each R4 is independently halogen, —CN, —NO2, —OH, —OCF3, —OCF2H, —OCH2F, —CF3, —SR8, —S(═O)R9, —S(═O)2R9, —NR10S(═O)2R9, —S(═O)2N(R10)2, —OR10, —C(═O)R9, —OC(═O)R9, —CO2R10, —N(R10)2, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10C(═O)OR10, —NR10C(═O)N(R10)2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl;
- R8 is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
- R9 is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
- each R10 is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or two R10 together with the atoms to which they are attached form a heterocycle;
- s is 0-4;
- ring B is aryl or heteroaryl;
- each R5 is independently halogen, —CN, —NO2, —OH, —SR8, —S(═O)R9, —S(═O)2R9, NR10S(═O)2R9, —S(═O)2N(R10)2, —C(═O)R9, —OC(═O)R9, —CO2R10, —N(R10)2, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10C(═O)OR10, —NR10C(═O)N(R10)2, —OR10, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl;
- r is 0-8;
- and
- R7 is H, halogen, —CN, substituted or unsubstituted alkyl, —C(═O)N(R10)2, —CO2R10, —OR10, —N(R10)2, acyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.
13 more elements
A compound having the structure of Formula IA or a pharmaceutically acceptable salt or N-oxide thereof:
- wherein:
- R1 and R2 are each independently H or substituted or unsubstituted alkyl;
- or R1 and R2 together with the carbon to which they are attached form a C3-C6 cycloalkyl ring;
- p is 1, 2 or 3;
- ring A is aryl or heteroaryl;
- R3 is —S(═O)R9 or —S(═O)2R9;
- each R4 is independently halogen, —CN, —NO2, —OH, —OCF3, —OCF2H, —OCH2F, —CF3, —SR8, —S(═O)R9, —S(═O)2R9, —NR10S(═O)2R9, —S(═O)2N(R10)2, —OR10, —C(═O)R9, —OC(═O)R9, —CO2R10, —N(R10)2, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10C(═O)OR10, —NR10C(═O)N(R10)2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl;
- R8 is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
- R9 is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
- each R10 is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or two R10 together with the atoms to which they are attached form a heterocycle;
- s is 0-4;
- ring B is aryl or heteroaryl;
- each R5 is independently halogen, —CN, —NO2, —OH, —SR8, —S(═O)R9, —S(═O)2R9, NR10S(═O)2R9, —S(═O)2N(R10)2, —C(═O)R9, —OC(═O)R9, —CO2R10, —N(R10)2, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10C(═O)OR10, —NR10C(═O)N(R10)2, —OR10, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl;
- r is 0-8;
- and
- R7 is H, halogen, —CN, substituted or unsubstituted alkyl, —OR10, —C(═O)N(R10)2, —CO2R10, —N(R10)2, acyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
- provided that the compound of Formula IA is not 2-(4-(4-methylpiperazin-1-yl)phenylamino)-8-(2-(methylsulfonyl)benzyl)pyrido[2,3-d]pyrimidin-7 (8H)-one, 8-(2-fluoro-6-(methylsulfinyl)benzyl)-2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one, or 8-(2-fluoro-6-(methylsulfinyl)benzyl)-2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrido[2,3-d]pyrimidin-7 (8H)-one.
14 more elements
A compound selected from:
- and pharmaceutically acceptable salts and N-oxides thereof.
Dependencies are inferred from the claim text.